Dr. C. Jimmy Lin
C. Jimmy Lin,
M.D., Ph.D., MHS is
Founder of the
Rare Genomics Institute (RGI) and
Research Instructor, Genomics and Pathology Services,
Washington University School of Medicine in St. Louis.
The Rare Genomics Institute
helps patients to crowdsource funds and genomes
to accelerate research of their rare genetic diseases.
They are a community dedicated to helping rare disease patients find
hope
for a cure. RGI works alongside patients and their families, providing
them with the necessary tools, knowledge, and connections so that
patients
can better understand the cause of their disease. They believe that
every
patient deserves more out of life.
Previously Jimmy was the the lead computational biologist for the
ground-breaking
cancer genome sequencing efforts from the Vogelstein Lab at Johns
Hopkins. Their sequencing of the first 100+ cancer exomes in 5 different
tissue types helped lay the foundation for a revolution in cancer
genomics.
His papers include
The Genomic Landscapes of Human
Breast and Colorectal Cancers,
The Consensus Coding Sequences of
Human Breast and Colorectal Cancers,
The genetic landscape of the childhood cancer
medulloblastoma,
Core signaling pathways in human pancreatic cancers revealed by
global
genomic analyses,
An integrated genomic analysis of human glioblastoma
multiforme,
Exome sequencing identifies GRIN2A as frequently mutated in
melanoma, and
Analysis of the tyrosine kinome in melanoma reveals recurrent
mutations in ERBB4.
Jimmy earned his BA/BS in
Cognitive Science, Molecular Biochemistry & Biophysics at
Yale University in 2001.
He earned his MHS in Bioinformatics at Johns Hopkins University in 2011.
He earned his M.D. and Ph.D. at The Johns Hopkins University School of
Medicine in 2012.
Watch
Dr. Jimmy Lin — Game-Changing Paradigms for Rare
Diseases and
Disruptive Heroes, C. Jimmy Lin.
Read
Turning point: Jimmy Lin.
Read
Curing Cancer Relies on Genome Mapping With DNA Evidence Guiding
Treatment.
View his
Facebook page.
Read his
Google+ profile,
LinkedIn profile, and his
TED profile.
Follow his
Twitter feed.
